Regulation of calcium absorption by 1,25,dihydroxy-vitamin D—Studies of the effects of a bisphosphonate treatment

Adami, Silvano; Frijlink, W. B.; Bijvoet, O. L. M.; O’Riordan, J. L. H.; Clemens, Thomas L.; Papapoulos, Socrates E.

doi:10.1007/bf02411260

Cited by 49 publications

(9 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to early bisphosphonates (ethane-hydroxy-1-bisphosphonate and EHBP), which markedly decrease serum 1,25-(OH)2D [33], recently developed bisphosphonates, such as 1-hydroxypentane-1,1-bisphosphonate (HPeBP) and (cycloheptylamine) methylene-1,1-bisphosphonic acid, YM-175) increase serum 1,25-(OH)2D and stimulate intestinal Ca transport in normal as well as parathyroidectomized rats [34,35,36]. Similar findings have been reported in patients with Paget's disease treated with AHPrBP [37]. Therefore, although AHPrBP decreases bone resorption, its stimulatory effect on renal and/or extrarenal 1a-hydroxylase and the subsequent increase in intestinal Ca absorption may have overcome the inhibitory effect on bone resorption, resulting in attenuation of the decrease in serum calcium.…”

Section: Methodssupporting

confidence: 59%

Progressively Increased Serum 1,25-Dihydroxyvitamin D2 Concentration in a Hypoparathyroid Patient with Protracted Hypercalcemia due to Vitamin D2 Intoxication.

Sato¹,

Emoto²,

Toraya³

et al. 1994

Endocr J

View full text Add to dashboard Cite

Abstract.A 76-year-old female patient who had been taking vitamin D2100,000 U/day for more than 14 years due to hypoparathyroidism following total thyroidectomy was admitted because of protracted hypercalcemia.On admission, the levels of serum vitamin D2 (99.8 ng/ml) and 25-OHD2 (356 ng/ml) were very high, and 1,25-(OH)2D2 was low (4.0-18.7 pg/ml). In addition, some bisphosphonates would certainly promote PTH-independent production of 1,25-(OH)2D2.

show abstract

Section: Methodssupporting

confidence: 59%

Progressively Increased Serum 1,25-Dihydroxyvitamin D2 Concentration in a Hypoparathyroid Patient with Protracted Hypercalcemia due to Vitamin D2 Intoxication.

Sato¹,

Emoto²,

Toraya³

et al. 1994

Endocr J

View full text Add to dashboard Cite

show abstract

“…2). This has been observed by others (Hamdy et al, 1987) and it might explain the relatively short-lived hypocalcaemic effect of bisphosphonate therapy in primary hyperparathyroidism in strict analogy to what has been observed in Paget's disease (Adami et al, 1982a). It is reasonable to suggest, with Hamdy et al (1987), that C12MBP induces an uncoupling between the rates of bone resorption and bone formation which disappears if treatment is continued for long enough to lower bone formation.…”

Section: Discussionmentioning

confidence: 57%

Regulation of Calcium‐parathyroid Hormone Feedback in Primary Hyperparathyroidism: Effects of Bisphosphonate Treatment

Adami

Mian

Bertoldo

et al. 1990

Clinical Endocrinology

Self Cite

View full text Add to dashboard Cite

Dichloromethylene bisphosphonate (C12MBP), a powerful inhibitor of bone resorption, was administered to 27 patients with primary hyperparathyroidism. It was given by either intravenous infusion (six patients, 500-100 mg day), or by intramuscular injection (six patients, 100-200 mg/day) or by mouth (15 patients, 1600-2400 mg/day) for 20-180 days. Sustained suppression of bone resorption was observed in all patients, as judged by a fall in the urinary hydroxyproline excretion. In contrast, the hypocalcaemic effect was inconsistent and short-lived, particularly in the patients without overt bone disease. The fall in serum calcium seemed largely to be due to a transient dissociation between bone resorption and bone formation and was associated with increases in circulating parathyroid hormone (PTH). In ten patients given the bisphosphonate orally for 6 months, serum calcium was unchanged but serum PTH was significantly raised. These results suggest that C12MBP may be of use for short-term correction of severe hypercalcaemia due to hyperparathyroidism, particularly in the patients with overt bone disease. However, its long-term use should not be recommended because of increased PTH secretion.

show abstract

“…Women receiving ALN þ D did not experience hypercalciuria, and in contrast, urinary calcium decreased by nearly 30 mg/d, similar to high-dose ergocalciferol, as reported by others. (21,22) As expected following bisphosphonate therapy, serum calcium levels decreased in women receiving alendronate (23) in contrast to the increase seen among women receiving placebo. Secondary endpoints of this investigation included changes in serum 25(OH)D and markers of bone resorption.…”

Section: Discussionmentioning

confidence: 72%

Effect of alendronate and vitamin D3 on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women

Shapses

Kendler

Robson

et al. 2011

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Menopause and increasing age are associated with a decrease in calcium absorption that can contribute to the pathogenesis of osteoporosis. We hypothesized that alendronate plus vitamin D 3 (ALN þ D) would increase fractional calcium absorption (FCA). In this randomized, double-blind, placebo-controlled multicenter clinical trial, 56 postmenopausal women with 25-hydroxyvitamin D [25(OH)D] concentrations of 25 ng/mL or less and low bone mineral density (BMD) received 5 weekly doses of placebo or alendronate 70 mg plus vitamin D 3 2800 IU (ALN þ D). Calcium intake was stabilized to approximately 1200 mg/d prior to randomization. FCA was determined using a dual-tracer stable-calcium isotope method. FCA and 25(OH)D were similar between treatment groups at baseline (0.31 AE 0.12 ng/ mL and 19.8 AE 4.7 ng/mL, respectively). After 1 month of treatment, subjects randomized to ALN þ D experienced a significant least squares (LS) mean [95% confidence interval (CI)] increase in FCA [0.070 (0.042, 0.098)], whereas FCA did not change significantly in the placebo group [À0.016 (À0.044, 0.012)]. After ALN þ D treatment, patients had higher 25(OH)D levels (LS mean difference 7.3 ng/mL, p < .001). The rise in serum 1,25-dihydroxyvitamin D 3 ( p < .02) and parathyroid hormone ( p < .001) were greater in the ALN þ D group than in placebo-treated patients. ALN þ D was associated with an increase in FCA of 0.07. To our knowledge, there is no other trial showing such a marked rise in calcium absorption owing to treatment with a bisphosphonate or owing to a small rise in 25(OH)D. This unique response of ALN þ D is important for the treatment of osteoporosis, but the exact mechanism requires further study. ß

show abstract

Regulation of calcium absorption by 1,25,dihydroxy-vitamin D—Studies of the effects of a bisphosphonate treatment

Cited by 49 publications

References 9 publications

Progressively Increased Serum 1,25-Dihydroxyvitamin D2 Concentration in a Hypoparathyroid Patient with Protracted Hypercalcemia due to Vitamin D2 Intoxication.

Progressively Increased Serum 1,25-Dihydroxyvitamin D2 Concentration in a Hypoparathyroid Patient with Protracted Hypercalcemia due to Vitamin D2 Intoxication.

Regulation of Calcium‐parathyroid Hormone Feedback in Primary Hyperparathyroidism: Effects of Bisphosphonate Treatment

Effect of alendronate and vitamin D3 on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women

Contact Info

Product

Resources

About